Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dovitinib lactate · 1 trial · 4 indications
All toxicities and adverse events will be summarized with frequencies and descriptive measures, and tabulated according to body system, severity and relation to treatment.
All toxicities and adverse events will be summarized with frequencies and descriptive measures, and tabulated according to body system, severity and relation to treatment.
| Arm | Type | Description |
|---|---|---|
| Treatment (dovitinib lactate, gemcitabine, and capecitabine) | EXPERIMENTAL | Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| dovitinib lactate | DRUG | Given PO |
| gemcitabine hydrochloride | DRUG | Given IV |
| capecitabine | DRUG | Given PO |
| laboratory biomarker analysis | OTHER | Correlative studies |
| enzyme-linked immunosorbent assay | OTHER | Correlative studies |
| pharmacological study | OTHER | Correlative studies |
Inclusion Criteria: * Part A: histologically or cytologically confirmed solid tumors that ale advanced or metastatic that the gemcitabine combination is considered standard therapy or a rational option * Part B: histologically or cytologically confirmed adenocarcinoma of the pancreas or the biliary...
Dovitinib lactate is an investigational small molecule being studied for use in adenocarcinoma of the pancreas, specifically in patients with advanced or metastatic pancreatic cancer. It was evaluated in a Phase 1 clinical trial in combination with gemcitabine hydrochloride and capecitabine for treating patients with advanced or metastatic solid tumors, pancreatic cancer, and biliary cancers.
Dovitinib lactate is being developed by Novartis AG, which trades under the ticker symbol NVS. The company sponsored a Phase 1 clinical trial of the drug in combination with other agents for the treatment of pancreatic cancer and other solid tumors.
Dovitinib lactate is in Phase 1 clinical development. It has completed a Phase 1 trial (NCT01497392) that evaluated the drug in combination with gemcitabine hydrochloride and capecitabine in patients with advanced or metastatic solid tumors, including pancreatic cancer. The drug is investigational and not yet approved.
Dovitinib lactate has been studied in one completed clinical trial, NCT01497392. This Phase 1 trial enrolled 26 participants and evaluated dovitinib lactate in combination with gemcitabine hydrochloride and capecitabine for treating patients with advanced or metastatic solid tumors, pancreatic cancer, and biliary cancers. The trial was conducted in the United States.
Dovitinib lactate is a small molecule that works by inhibiting multiple receptor tyrosine kinases, which are enzymes involved in cell signaling and tumor growth. By blocking these targets, the drug aims to interfere with cancer cell proliferation and survival. This mechanism was evaluated in the context of pancreatic cancer and other solid tumors.